SAS
XERS icon

Spurstone Advisory Services’s Xeris Biopharma Holdings XERS Stock Holding History

Spurstone Advisory Services’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16K Hold
200
– – 0.02% 48
2025
Q4 		$1.57K Hold
200
– – 0.02% 65
2025
Q3 		$1.63K Hold
200
– – 0.02% 81
2025
Q2 		$934 Hold
200
– – 0.01% 110
2025
Q1 		$1.1K Hold
200
– – 0.02% 73
2024
Q4 		$678 Buy
+200
New +$643 0.01% 64

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spurstone Advisory Services's XERS Position: Q1 2026 in Review

Spurstone Advisory Services held its Xeris Biopharma Holdings (XERS) position steady in Q1 2026 at 200 shares worth $1.16K. The position accounts for 0.02% of the portfolio, ranked #48.

Spurstone Advisory Services first reported a position in XERS in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.63K in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Spurstone Advisory Services held 200 shares of Xeris Biopharma Holdings worth $1.16K as of Q1 2026.
  • Spurstone Advisory Services left its Xeris Biopharma Holdings share count unchanged in Q1 2026.
  • Xeris Biopharma Holdings made up 0.02% of Spurstone Advisory Services's portfolio in Q1 2026, its #48 holding.
  • Spurstone Advisory Services first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 6 quarters since.
  • Spurstone Advisory Services's Xeris Biopharma Holdings position peaked at $1.63K in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Spurstone Advisory Services's 13F filing for Q1 2026, filed 28 Apr 2026.